The Effect of Specific Immunotherapy on Natural Killer T cells in Peripheral Blood of House Dust Mite-Sensitized Children with Asthma

Lu Yan-ming, Cao Lan-fang, Li Chen, Li Ya-qin, Chen Wei, and Zhang Wen-ming

Department of Pediatrics, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200001, China

Correspondence should be addressed to Cao Lan-fang, lanfangcao@yahoo.com

Received 6 June 2012; Revised 1 August 2012; Accepted 2 August 2012

Academic Editor: T. Nakayama

Copyright © 2012 Lu Yan-ming et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

To investigate the effects of specific immunotherapy on the NKT cells in peripheral blood and the ability of NKT cells to proliferate in response to alpha-galactosylceramide (alpha-GalCer) in house-dust-mite- (HDM-) sensitized asthma children, peripheral blood mononuclear cells were isolated from 42 asthmatic children, of whom 24 were on specific immunotherapy (SIT) for more than a year and 20 were healthy. Compared with control group, the ratio of peripheral blood NKT and CD4+NKT cells was significantly decreased \( (P < 0.01) \) and was elevated in SIT asthma group \( (P < 0.05) \), respectively, but it was still less than the normal control group \( (P < 0.01) \). The level of IL-4 in serum secreted by NKT cells in asthma group was significantly higher than that of control group \( (P < 0.01) \), particularly apparent after 72 hours. The level of IL-4 in SIT group decreased significantly \( (P < 0.01) \). The level of IL-10 in serum secreted by NKT cells in asthma group was decreased significantly than that of the control group \( (P < 0.01) \) especially in 48 hours, while that of SIT group was increased significantly \( (P < 0.01) \). These results suggest that the pathogenesis of asthma may be related to the ratio and dysfunction of NKT and CD4+NKT cells.

1. Background

Natural Killer (NKT) T cells express not only NK1.1 antigen (CD161 in human, NKR-PIC in mouse), a unique marker of NK cells, but also the T-cell receptor (TCR). The NKT cells are divided into two types: type I NKT cells and type II NKT cells. Type I NKT cells express constant TCR α chain, which are also named as invariant natural killer T cells (iNKT), constituting about 70–80% of all NKT cells. T-cell receptor of Human iNKT cells consists of constant Va24-Jα18 chain and Vβ11 chain, while rodents consist of Va14-Jα18 and Vβ8.2, Vβ7 or Vβ2 chain, which mainly recognize α-GalCer presented by CD1d. Human NKT cells can be further divided into three subtypes: CD4+NKT cells, CD4−CD8+NKT (DN NKT) cells, and CD8+NKT cells [1].

iNKT comprises of T lymphocyte lineage which is extremely restricted to T-cell antigen receptor with limited junctional diversity (Va24-Jα18 in human and Va14-Jα18 in mouse). One of the features that distinguishes iNKT from conventional T cells is their capacity to rapidly and in some cases simultaneously produce large amounts of both T helper (Th) 1 proinflammatory (promoting cellular immune responses) and Th2-type anti-inflammatory (promoting certain antibody responses) cytokines upon triggering, thereby mediating the regulation of a variety of immune responses, including antitumor immune responses [2].

It has been seen that the specific role of NKT cells in the development of asthma is complex. Although the development of Th2-driven responses to allergens is an important factor in the development of asthma, iNKT cells may provide a lung-specific mechanism that allows asthma to develop in allergic individuals. In this process, iNKT cells may in some way process Th2 cells to induce AHR or may enhance Th2 cell development [3]. Investigations on occurrence, development, and treatment options of asthma with various means of immunomodulation have gradually attracted the attention of clinicians. The WHO explicitly pointed out that the standard specific immunotherapy (SIT) is the only way
to change the natural processes of allergic diseases that occur due to the treatment. The SIT can improve the quality of life: relieving the symptoms of patients with asthma, improving lung function, and reducing the use of emergency drugs. However, sometimes SIT cannot completely control asthma, and some patients still require long-term conventional drug treatment after SIT treatment. In addition, SIT can also cause systemic and/or local side effects, or even fatal anaphylactic shock. The efficacy and safety of SIT in the treatment of allergic asthma has yet to be solved, one reason could be nonunderstanding of the exact mechanism of SIT in asthma treatment. Therefore, to explore further the mechanism of SIT in asthma treatment has great significance in improving its efficacy and safety and further elucidating the pathogenesis of asthma.

Using TCR Va24+/TCR Vβ11+ double-positive cells as NKT cells, we observed changes in the number of NKT cells and CD4+ NKT cells TCR Va24/TCR Vβ11 cells by immunofluorescent labeling and flow cytometry method in children with asthma, children with asthma treated with standard SIT for more than 1 year, and normal children. Following which, we observed expression pattern change of cytokines (IL-4, IL-10, IFN-γ) produced by NKT cells after stimulating peripheral blood mononuclear cells with α-GalCer, specific agonist of NKT cells. α-GalCer is often used to test and isolate and activate NKT cell specifically working as specific activator of NKT cell. They were stimulated repeatedly by α-GalCer in vitro which can reflect the secretion of the NKT cell indirectly. Accordingly, the theoretical and experimental basis was provided for exploring the regulatory role of NKT cells in the pathogenesis of asthma in children and specific immunotherapy.

2. Materials and Methods

All 66 cases were children (39 male and 27 female) with asthma diagnosed by Pediatric clinic of our hospital from February 2009 to March 2012. All the children were aged 8.57 ± 3.01 years (range: 5 to 16 years) and met the diagnosis and prevention guidelines for children with bronchial asthma developed by the Respiratory Group of Pediatrics Branch, Chinese Medical Association [4], with or without allergic rhinitis. The medical history of the cases was with dust mite allergy through history, allergen skin prick test (SPT), and the in vitro serum allergen-specific IgE determination. Other inclusion criteria were presence of at least one mite allergy (household dust mites, dust mites, tropical mites) and the range of SPT wheal reaction ≥ ++ compared with histamine. Patients who had autoimmune diseases except allergic diseases, mental disorders, heart, liver and kidney disorders were excluded. Caretakers for all the patients signed informed consent.

2.1. Asthma Group. Patients without the implementation of SIT-, 26 cases were classified as mild intermittent, 10 cases as mild persistent, and 6 cases as moderate persistent in accordance with the asthma severity. The whole group underwent careful history taking, physical examination, and even a chest X-ray to exclude pulmonary infection when necessary.

2.2. SIT Group. This group included 24 children with asthma (12 males and 12 females) with average age 10.8 ± 3.40 years (range: 5–16 years), application of standard allergen preparations for dustmite (Alutard, ALK-Abello Company, Denmark) for at least 1 year.

2.3. Control Group. Twenty healthy children (12 males and 8 females) with mean age 8.95 ± 3.81 years had no recent infection or a history of allergic disease.

2.4. Main Reagents and Instruments. Lymphocyte separation medium Ficoll-Hypaque (Shanghai Second Reagent Factory); erythrocyte lysis buffer (Cogent Bio); anti-human CD4-APC (eBioscience); TCRVa24-PE and TCRVβ11-FITC (Backmancouler, U.S.); alpha-Galcer (Enzo Company, USA); RPMI-1640 medium, fetal bovine serum (Gibco, USA); ELISA Kit for IL-4, IL-10, IFN-gamma (RD Corporation, USA); flow cytometer BDFACS Caliber flow (BD, USA).

2.5. Experimental Methods

2.5.1. Peripheral Blood Mononuclear Cells (PBMNCs) Separation. Peripheral blood about 4-5 mL was collected aseptically in children with asthma and those who were normal. Anticoagulation was done with heparin, cascaded onto the lymphocyte separation solution after PBS-fold diluted, centrifuged at 2000 r/min for 20 min, r = 15.5 cm. The albuginea cell layer was collected and washed with PBS and resuspended in RPMI-1640 medium which was then counted for the future use.

2.5.2. NKT Cell Detection. 100 uL of peripheral blood was freshly collected aseptically from children in asthma and normal group into flow cytometry tubes; added 10 μL of CD4-APC antibody, TCRVa24-PE antibody, and TCRVβ11-FITC antibody; added 1 mL erythrocyte lysis solution after mixture and incubation. After full lysis, excluded supernatant after centrifugation for 3 minutes at 2500 r/min, r = 13.8 cm was washed with 2 mL PBS, then NKT cells and CD4+NKT cells were detected with flow cytometry. The anti-human TCR V24V-11-monoclonal antibody was the specific marker of NKT cells.

2.5.3. Amplification and Activation of Nkt Cells. Mononuclear cells (5x10^5) collected from peripheral blood were cultured in RPMI-1640 medium containing 10% fetal bovine serum with α-Galcer (final concentration: 100 ng/mL) in 25 cm² culture flask bottle, placed into 5% CO₂, at 37°C incubator. The culture supernatant was collected at 24 h, 48 h, and 72 h, respectively,

Detection of the Level of IL-4, IFN-γ. IL-10 in the Culture Supernatant with ELISA. It was measured according to ELISA kit instruction (RD Company, USA).
2.5.4. Clinical Data Collection. The allergic indicators total IgE and ECP of children with asthma were detected after collecting the blood.

2.5.5. Statistic Analysis. The result for each group was expressed as $\bar{x} \pm s$ (mean $\pm$ sd), analyzed with statistical software SPSS13.0. Complete random control variance analysis was applied for the mean comparison among multiple groups. Comparison between two groups was done with the Mann-Whitney U test. Correlation analysis of two-variable was done with linear correlation analysis method. $P < 0.05$ was considered to be statistically significant.

3. Results

The baseline characteristics of the patients have been reported in the Table 1. There were no significant difference, in demographics and severity of the disease between asthma group and the SIT group.

| Group   | N | Age (mean ± sd) | Gender (Male/Female) | T IgE (IU/mL) | Ecp (ug/L) |
|---------|---|----------------|----------------------|--------------|------------|
| Control | 20| 8.95 ± 3.81    | 12/8                 | 461.45 ± 476.33 | 28.37 ± 25.34 |
| Asthma  | 42| 8.57 ± 3.01    | 27/15                | 518.56 ± 426.35 | 43.22 ± 30.97 |
| SIT     | 24| 10.08 ± 3.40   | 12/12                |              |            |

Table 1: Baseline characteristics of the patients.

| Group | N  | NKT (mean ± sd) | CD4+NKT (mean ± sd) |
|-------|----|-----------------|---------------------|
| Control | 20 | 0.135 ± 0.061   | 63.28 ± 16.87       |
| Asthma | 42 | 0.051 ± 0.041   | 42.21 ± 13.72       |
| SIT    | 24 | 0.091 ± 0.059   | 50.45 ± 16.70       |

Table 2: The ratio of peripheral blood NKT and CD4+NKT cells in asthma patients and control group ($\bar{x} \pm sd$).

| Group         | N  | NKT (mean ± sd) | CD4+NKT (mean ± sd) |
|---------------|----|-----------------|---------------------|
| Intermittent  | 26 | 0.057 ± 0.045   | 44.21 ± 14.15       |
| Mild persistent | 10 | 0.046 ± 0.037   | 41.39 ± 11.39       |
| Moderate persistent | 6  | 0.035 ± 0.029   | 34.39 ± 14.99       |
| F             |    | 0.757           | 1.148               |
| P             |    | 0.476           | 0.328               |

Table 3: ($\bar{x} \pm sd$).

3.1. The Ratio of Peripheral Blood NKT and CD4+NKT Cells in Asthma Patients and Control Group. Compared with normal control group, the rate of NKT and CD4+NKT cells significantly decreased in children with asthma ($P < 0.01$). The ratio of NKT cells and CD4+NKT cells in SIT group was higher than that in asthmatic group ($P < 0.05$), but still lower than that in the normal control group ($P < 0.01$, Table 2).

3.2. The Ratio of Peripheral Blood NKT and CD4+NKT Cells in Asthma Patients according to Asthma Severity. In the group of children with asthma, the ratio of peripheral blood NKT cells and CD4+NKT cells of moderate persistent patients was slightly lower than that of mild intermittent and that of mild persistent, but there was no significant difference in the ratio of peripheral blood NKT cells and CD4+NKT cells among the three groups ($P > 0.05$, Table 3).

3.3. Correlation Analysis. There was no significant correlation among NKT cells and total IgE and ECP ($r = 0.022$), $P > 0.05$, and there was no significant correlation among NKT cells and total IgE and ECP as well ($r = 0.022$, $P > 0.05$, $r = 0.107$, $P > 0.05$).

3.4. The Level of IFN-γ, IL-4, and IL-10 Expression after NKT Cells Proliferation in Asthma Patients and Control. Level of IL-4 secreted by NKT cells after proliferation activation in children with asthma was significantly higher than normal control group ($P < 0.01$), particularly at 72 h; compared with asthma patients. The IL-4 secretion decreased significantly ($P < 0.01$) in SIT group and it showed no significant difference between normal group and SIT group ($P > 0.05$) compared with normal control group. The secretion of IL-10 by NKT cell in asthma group patients decreased ($P < 0.01$), especially at 48 h, while IL-10 in SIT group increased significantly compared with asthma patients ($P < 0.01$), and there was no significant difference in IL-10 secretion between normal control group and SIT group ($P > 0.05$). It showed no significant difference in the IFN-γ secretion by NKT cells between asthma group and the SIT group ($P > 0.05$). Further, there was no significant correlation between NKT number and improvement of disease (Table 4).

4. Discussion

Specific immunotherapy is currently the only treatment method to intervene in allergic disease through the physiological mechanisms. Therefore, it is widely used in clinical treatment of type I allergic diseases including bronchial asthma, mediated by IgE. The SIT treatment mechanism is complex, and most researchers are mainly focused on the role of T cells followed by cytokine changes. The NKT cells are newly discovered group of special types of immune cells, after the activation, which can rapidly produce a large number of cytokines with immune-modulatory effects; including Th1-type cytokines (IFN-γ and TNF) and Th2-type cytokines (IL-4, IL-13), therefore, influencing Th1/Th2...
Table 4: The level of IFN-γ, IL-4, IL-10 expression after NKT cells proliferation in asthma patients and control (\( \bar{x} \pm sd \)).

| Group    | IFN-γ (pg/mL) | IL-4 (pg/mL) | IL-10 (pg/mL) |
|----------|---------------|--------------|---------------|
|          | 24 H          | 48 H         | 72 H          | 24 H          | 48 H         | 72 H          | 24 H          | 48 H         | 72 H          |
| Control  | 142.28 ± 54.31| 410.11 ± 217.21| 219.31 ± 96.12| 11.96 ± 7.35 | 77.36 ± 37.42 | 93.05 ± 44.91 | 35.28 ± 18.27 | 100.71 ± 60.28 | 95.57 ± 60.90 |
| Asthma   | 126.60 ± 40.63| 374.79 ± 104.80 | 209.38 ± 96.61 | 28.71 ± 10.47 | 135.29 ± 40.90 | 277.60 ± 89.15 | 14.16 ± 5.29 | 28.60 ± 20.34 | 20.90 ± 11.50 |
| SIT      | 149.92 ± 73.74| 406.24 ± 211.08 | 226.82 ± 106.34 | 14.52 ± 8.68 | 99.80 ± 48.25 | 101.79 ± 57.90 | 39.04 ± 28.65 | 95.41 ± 49.62 | 76.28 ± 32.36 |

F: 0.790 0.212 0.135 17.44 17.309 40.535 9.090 14.652 18.201
P: 0.46 0.809 0.874 0.000 0.000 0.000 0.000 0.000 0.000

Note: compare with control group ▲*P < 0.01;
compare with asthma group ⋆*P < 0.01.
immune balance. The production of cytokines in NKT is significantly faster than conventional T cells. Further, in the SIT group, children were assessed by the parents subjectively: in 11 (45.8%) children significant improvement was reported by the families, 8 children (33.3%) showed moderate improvement, 4 (16.7%) indicated a slight improvement, and 1 patient (4.2%) had no change in the condition.

The NKT cells in human peripheral blood are very few, only about 0.04%–0.2% [5]. Therefore, clinical research on NKT cells has been limited for a long time. However, NKT cells in vitro with repeated stimulation by α-GalCer will rapidly proliferate and can also show increased secretion of cytokines. The establishment of in vitro amplification of NKT cells may be able to lay a foundation for further clinical studies. The α-GalCer, is a kind of glycosphingolipid (GSL) extracted from the sponge, often used for specific identification, isolation, and activation of NKT cells. According to a recent study, in vivo or in vitro experiments, demonstrate that the extremely small amount of α-GalCer will be able to involve in the binding of the NKT cells CD1d, which prompts amplification and activation of NKT cells, and consequently secrete large amounts of cytokines rapidly [6]. The KRN7000 is a new α-GalCer reagent, and it is also the most effective α-GalCer ligand for activation of NKT cells [7]. This study made the anti-human TCR Vα24Vβ11 monoclonal antibody a specific marker of NKT cells, nucleated cells were collected using the erythrocyte lysis liquid to obtain a sufficient number of cells, and the use of flow cytometry improved the sensitivity of the NKT cells detection.

The study showed that the ratio of either NKT cells or CD4+ NKT cells in children with asthma was significantly lower than the control group (P < 0.01), while the ratio of peripheral blood NKT cells and CD4+ NKT cells showed no significant difference among children with different severity of asthma (P > 0.05), which may be associated with the small number of cases in this study. After SIT for more than one year, the ratio of NKT cells and CD4+ NKT cells has increased, but it was still lower than the normal control group (P < 0.01). These results suggest that NKT cells and CD4+ NKT cells may be involved in the pathogenesis of asthma. In addition, the results of this study showed no significant correlation between the ratio of NKT cells and CD4+ NKT cells and total IgE and ECP, the common indicators of asthma (P > 0.05), similar to research by Ikegami et al. [8]. Thus, we have speculated that NKT cells may migrate and aggregate to the sites of inflammation. Asthma patients had significant mucosal inflammation in respiratory tract, therefore, NKT cells migrate and aggregate from peripheral blood gradually to the sites of inflammation of the respiratory mucosa to play its role in immune regulation, and ratio of NKT cells and CD4+ NKT cells in peripheral blood further reduce, which is consistent to Akbari et al. study [9]. After SIT treatment, the migration and aggregation of NKT cells have been suppressed, so the ratio of NKT cells and CD4+ NKT cells in the peripheral blood also increased.

Although the number of peripheral blood NKT cells is small, NKT cells can rapidly proliferate and show good immune response after repeated stimulation with α-GalCer in vitro. The NKT cells constitutively exist in the mRNA

5. Conclusion

In summary, this study indicated that there was a reduction in number of peripheral blood NKT cells and CD4+ NKT cells in patients with asthma, as well as change of cell function. Human NKT cells can produce cytokines IL-4 and IL-10, which promote Th2 cell generation and play an important role in the pathogenesis of asthma. Specific immunotherapy can correct the bias of the NKT cells number and their functions in the patients with asthma. However, due to the small size of sample, we did not compare the patients with asthma after SIT with those before SIT. We will further improve our research in order to draw more definitive conclusions in the future.
**Abbreviations**

alpha-GalCer: Alpha-galactosylceramide  
HDM: House dust mite  
SIT: Specific immunotherapy  
NKT: Natural killer T cells  
TCR: T-cell receptor  
iNKT: Invariant natural killer T cells  
GSL: Glycosphingolipid.

**Conflicts of Interests**

The authors declared that there are no conflict of interest.

**References**

[1] D. I. Godfrey, H. R. MacDonald, M. Kronenberg, M. J. Smyth, and L. Van Kaer, “NKT cells: what’s in a name?” *Nature Reviews Immunology*, vol. 4, no. 3, pp. 231–237, 2004.

[2] H. J. J. Van Der Vliet, S. P. Balk, and M. A. Exley, “Natural killer T cell-based cancer immunotherapy,” *Clinical Cancer Research*, vol. 12, no. 20, pp. 5921–5923, 2006.

[3] D. T. Umetsu and R. H. DeKruyff, “The regulation of allergy and asthma,” *Immunological Reviews*, vol. 212, pp. 238–255, 2006.

[4] Respiratory group of Pediatrics Branch, Chinese Medical Association.Editorial Committee of the Pediatrics, “Diagnosis and prevention guidelines for Children with bronchial asthma,” *Pediatrics*, vol. 46, no. 10, pp. 745–753.

[5] A. Bendelac, P. B. Savage, and L. Teyton, “The biology of NKT cells,” *Annual Review of Immunology*, vol. 25, pp. 297–336, 2007.

[6] Y. Liu, R. D. Goff, D. Zhou et al., “A modified α-galactosyl ceramide for staining and stimulating natural killer T cells,” *Journal of Immunological Methods*, vol. 312, no. 1-2, pp. 34–39, 2006.

[7] A. Shimosaka, “Role of NKT cells and alpha-galactosyl ceramide,” *International Journal of Hematology*, vol. 76, pp. 277–279, 2002.

[8] Y. Ikegami, A. Yokoyama, Y. Haruta, K. Hiyama, and N. Kobno, “Circulating natural killer T cells in patients with asthma,” *Journal of Asthma*, vol. 41, no. 8, pp. 877–882, 2004.

[9] O. Akbari, J. L. Faul, E. G. Hoyte et al., “CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma,” *The New England Journal of Medicine*, vol. 354, no. 11, pp. 1117–1129, 2006.

[10] Y. Huang, E. L. Jiang, Z. Zhou et al., “Modulation of cytokine 2producing of VA24 natural killer T,” *Journal of Clinical Hematology*, vol. 21, no. 3, pp. 264–267, 2008.

[11] A. O. Magnan, L. G. Mély, C. A. Camilla et al., “Assessment of the Th1/Th2 paradigm in whole blood in atopy and asthma: increased IFN-γ-producing CD8+ T cells in asthma,” *American Journal of Respiratory and Critical Care Medicine*, vol. 161, no. 6, pp. 1790–1796, 2000.

[12] J. L. M. Vissers, B. C. A. M. Van Esch, G. A. Hofman, M. L. Kapsenberg, F. R. Weller, and A. J. M. Van Oosterhout, “Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model,” *Journal of Allergy and Clinical Immunology*, vol. 113, no. 6, pp. 1204–1210, 2004.